The European Society for Medical Oncology [14] and the WHO classification [4] emphasize the systematic assessment of specific molecular alterations in NSCLC, such as genetic mutations (e.g., EGFR, KRAS), fusions (e.g., ALK, ROS1, RET), and protein overexpression such as programmed death-ligand 1 (PD-L1), among others. This evidence concerns the gene ALK and non-small cell lung carcinoma.